Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Lecanemab shows 67% patient retention at 24 months in US study
Eisai Co., Ltd. and Biogen Inc. presented real-world data indicating that 67.3% of patients treated with lecanemab (LEQEMBI) maintained treatment for 24 months in a US study. This retrospective analysis of over 10,000 patients is the first real-world persistence data beyond 18 months for the Alzheimer’s drug. Eisai, the lead developer, maintains a strong financial profile and continues to commercialize the drug with Biogen, with new formulations and regulatory reviews ongoing.